Current and future treatment of hyperlipidemia: The role of statins

American Journal of Cardiology

Volumn 82, Issue 4 B, 1998, Pages 3J-10J

  Farnier, Michel ^a   Davignon, Jean ^b  

^a Point Medical   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DRUG EFFECT; DRUG SAFETY; ENZYME INHIBITION; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOLIPEMIA; LIPID METABOLISM; LIVER TOXICITY; MYOPATHY; NEPHROTOXICITY; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 0032572717     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00423-8     Document Type: Conference Paper

References (73)

1. Thom T.J., Kannel W.B. Downward trend in cardiovascular mortality. Ann Rev Med. 32:1981;427-434.
2. Uemura K., Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q. 41:1988;155-178.
3. Uemura K. International trends in cardiovascular diseases in the elderly. Eur Heart J. 9:(suppl):1988;1-8.
4. Department of HEW, National Center for Health Statistics. Chartbook for the Conference on the decline in coronary heart disease mortality. 1979;42.
5. Badimon J.J., Fuster V., Cheseboro J.H., Badimon L. Coronary atherosclerosis. A multifactorial disease. Circulation. 87:(suppl):1993;II3-II16.
6. Anderson K.M., Castelli W.P., Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham Study. JAMA. 257:1987;2176-2180.
7. Martin M.J., Hulley S.B., Browner W.S., Kuller L.H., Wentworth D. Serum cholesterol, blood pressure and mortality implications from a cohort of 361,662 men . Lancet. ii:1986;933-936.
8. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
9. Watts G.F., Lewis B., Brunt J.N., Lewis E.S., Coltart D.J., Smith L.D., Mann J.I., Swan A.V. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 339:1992;563-569.
10. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 264:1990;3007-3012.
11. Blankenhorn D.H., Azen S.P., Kramsch D.M., Mack W.J., Cashin-Hemphill L.C., Hodis H.N., DeBoer L.W.V., Mahrer P.R., Masteuer M.J., Vailas L.I., Alaupovic P., Hirsch L.J. Coronary angiographic changes with lovastatin therapy the Monitored Atherosclerosis Regression Study (MARS) . Ann Intern Med. 119:1993;969-976.
12. Waters D., Higginson L., Gladstone P., Kimball B., Le May M., Boccuzzi S.J., Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography the Canadian Coronary Atherosclerosis Intervention Trial . Circulation. 89:1994;959-968.
13. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 268:1992;1429-1433.
14. Schuler G., Hambrecht R., Schlierf G., Niebauer J., Hauer K., Neumann J., Hoberg E., Drinkmann A., Bacher F., Grunze M., Kubler W. Regular physical exercise and low-fat diet effects on progression of coronary artery disease . Circulation. 86:1992;1-11.
15. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 308:1994;367-372.
16. Rossouw J.E., Lewis B., Rifkind B.M. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 323:1990;1112-1119.
17. Beaumont J.L., Carlson L.A., Cooper G.R., Fejfar Z., Frederickson D.S., Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ. 43:1970;891-915.
18. Williams G., Monson J.P. Diabetes mellitus and disorders of lipid and intermediary metabolism. Souhamin R.L., Moxham J. Textbook of Medicine. 2nd Ed :1994;739-784 Churchill Livingstone, Edinburgh.
19. The Lipids Research Clinics Coronary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA. 251:1984;351-364.
20. The Lipids Research Clinics Coronary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 251:1984;365-374.
21. Manninen V., Elo M.O., Frick M.H., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 260:1988;641-651.
22. Assmann G., Schulte H., Cullen P. New and classical risk factors - the Munster heart study (PROCAM). Eur J Med Res. 2:1997;237-242.
23. Austin M.A. Plasma triglycerides and coronary heart disease. Arterioscler Thromb Vasc Biol. 11:1991;2-14.
24. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R. Jr, Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
25. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Manttari M., Heinonen O.P., Frick M.H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentration on coronary heart disease risk in the Helsinki Heart Study implications form treatment . Circulation. 85:1992;37-45.
26. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
27. Sniderman A.D., Ghezzo R.H. Meta analysis of the clinical outcomes of recent quantitative angiographic trials to lower plasma LDL in patients with CAD. Can J Cardiol. 10:(suppl B):1994;10B-16B.
28. Larsen M.L., Illingworth D.R. Drug treatment of dyslipoproteinemia. Med Clin N Am. 78:1994;225-245.
29. Endo A., Kuroda M., Tsujita Y. ML-236A, ML-236B, ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot. 29:1976;1346-1348.
30. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 319:1988;24-33.
31. Slater E.E., MacDonald J.S. Mechanism of action and biological profile of HMG-CoA reductase inhibitors a new therapeutic alternative . Drugs. 36:(suppl 3):1988;72-82.
32. Hsu I., Spinler S.A., Johnson N.E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 29:1995;743-759.
33. Illingworth D.R., Tobert J.A. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 16:1994;366-385.
34. Blum C.B. Comparison of the properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 73:(suppl):1994;3D-11D.
35. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin in new HMG-CoA reductase inhibitor. Atheroscler Thromb Vascular Biol. 15:1995;678-682.
36. Bischoff H., Angerbauer R., Bender J., Bischoff E., Faggiotto A., Petzinna D., Pfitzner J., Porter M.C., Schmidt D., Thomas G. Cerivastatin pharmacology of a novel synthetic and high active HMG-CoA reductase inhibitor . Atherosclerosis. 135:1997;119-130.
37. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., Keilson L.M., Brown W.V., Miller V.T., Shurzinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
38. Bocuzzi S.J., Bocanegra T.S., Walker J.F., Shapiro D.R., Keegan M.E. Long-term safety and efficacy profile of simvastatin. Am J Cardiol. 68:1991;1127-1131.
39. Dujovne C.A., Chremos A.N., Pool J.L., Schapner H., Bradford R.H., Shear C.L., Higgins J., Downton M., Franklin F.A., Nash D.T., Gould A.L., Langendörfer A. Expanded clinical evaluation of lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin. Am J Med. 91:(suppl 1B):1991;25S-30S.
40. Illingworth D.R., Bacon S.P., Larsen K.K. Long term experience with HMG-CoA reductase inhibitors in the therapy of hypercholesterolemia. Atheroscler Rev. 18:1988;161.
41. Lea A.P., McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs. 53:1997;828-847.
42. Gerson R.J., MacDonald J.S., Alberts A.W., Chen J., Yudkovitz J.B., Greenspan M.D., Rubin L.F., Bokelman D.L. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res. 50:1990;65-78.
43. Manson J.E., Tosteson H., Ridker P.M., Satterfield S., Herbert P., O'Connor G.T., Buring J.E., Hennekens C.H. The primary prevention of myocardial infarction. N Engl J Med. 326:1992;1406-1416.
44. Muldoon M.F., Manuck S.B., Matthews K.A. Lowering cholesterol concentration and mortality a quantitative review of primary prevention trials . Br Med J. 301:1990;309-314.
45. Pedersen T.R. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
46. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
47. Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris . Am J Cardiol. 76:1995;474-478.
48. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis - results of the LIPID atherosclerosis substudy. Circulation. 97:1998;1784-1790.
49. Shepherd J., Cobb S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
50. Downs J.R., Beere P.A., Whitney E., Clearfield M., Weis S., Rochen J., Stein E.A. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 80:1997;287-293.
51. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
52. Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 278:1997;313-321.
53. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
54. O'Keefe J.H., Conn R.D., Lavie C.J., Bateman T.M. The new paradigm for coronary artery disease altering risk factors, atherosclerotic plaques and clinical prognosis . Mayo Clin Proc. 71:1996;957-965.
55. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
56. Egashira K., Hirooka Y., Kai H., Sugimachi M., Suzuki S., Inou H., Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
57. O'Driscoll G., Green D., Taylor R. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
58. Andrews T.C., Raby K., Barry J., Naimi C.L., Allred E., Ganz P., Selwyn A.P. Effect of cholesterol reduction on myocardial infarction in patients with coronary disease. Circulation. 95:1997;324-328.
59. Reduction of transient myocardial ischaemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 94:1996;1503-1505.
60. Carvalho A.C.A., Colman R.W., Lees R.S. Platelet function in hyperlipoproteinemia. N Engl J Med. 290:1974;434-438.
61. Davi G., Averna M., Catalano I., Barbagallo C., Ganci A., Notarbartolo A., Ciabattoni G., Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 85:1992;1792-1798.
62. 2 by platelets in vitro. N Engl J Med. 302:1980;6-10.
63. Lacoste L., Lam J.Y.T., Hung J., Letchacovski G., Solymoss C.B., Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 92:1995;3172-3177.
64. Mayer J., Eller T., Brauer P., Solleder E.M., Schafer R.M., Keller F., Kochsiek K. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 64:1992;196-201.
65. Wada H., Mori Y., Kaneko T., Wakita Y., Minamikawa K., Ohiwa M., Tamaki S., Yokoyama N., Kobayashi T., Deguchi K. Hypercoagulable state in patients with hypercholesterolemia effects of pravastatin . Clin Ther. 14:1992;829-834.
66. Bevilacqua M., Bettica P., Milani M., Vago T., Rogolino A., Righini V., Santoli E., Norbiato G. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol. 79:1997;84-87.
67. Raines E.W., Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J. 69:1993;30-37.
68. Negre-Aminou P., van Vliet A.K., van Erck M., van Thiel G.C.F., van Leeuwen R.E.W., Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors comparison with other human cell types . Biochim Biophys Acta. 1345:1997;259-268.
69. Duggan D.E., Vickers S. Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev. 22:1990;333-362.
70. Sirtori C.R. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther. 60:1993;431-459.
71. Physicians' Desk Reference. Package inserts for LESCOL (fluvastatin sodium), MEVACOR (fluvastatin sodium), PRAVACHOL (pravastatin sodium), ZOCOR (simvastatin). Edition 50, Montvale, NJ: Medical Economics Company, 1996.
72. Cerivastatin. Bayer AG, data on file.
73. Wierzbicki A.S. Diagnosis and management of hyperlipidaemia. Int J Clin Pract. 51:1997;378-383.